![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO) Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO...
Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care The acquisition of LumiraDx’s Point of Care technology received all required...
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year earnings outlook raised Group sales were up by 5%1...
New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye...
Roche’s Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study More than 90% of patients had absence of DME after...
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity After four weeks of...
Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes The Accu-Chek® SmartGuide CGM solution provides 14...
Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD) The FDA has approved updates to Susvimo, which will be available to US retina specialists...
FDA approves Roche’s Vabysmo prefilled syringe (PFS) for three leading causes of vision loss Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat...
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer SKYSCRAPER-06 evaluating tiragolumab...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 229.2 | 229.2 | 229.2 | 1427 | 229.2 | DE |
4 | 0 | 0 | 229.2 | 229.2 | 229.2 | 1513 | 229.2 | DE |
12 | 0 | 0 | 229.2 | 229.2 | 229.2 | 3355 | 229.2 | DE |
26 | 0 | 0 | 229.2 | 229.2 | 229.2 | 5067 | 229.2 | DE |
52 | 0 | 0 | 229.2 | 229.2 | 229.2 | 5288 | 229.2 | DE |
156 | 0 | 0 | 229.2 | 229.2 | 229.2 | 5980 | 229.2 | DE |
260 | 0 | 0 | 229.2 | 229.2 | 229.2 | 4627 | 229.2 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions